Detection and utility of predictive biomarkers have shown clinical improvement and survival benefits for matched targeted therapies in several types of malignancies (BRAF in melanoma or EGFR in non-small cell lung cancer) [3]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.